Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:C43 Stock Latest News

Company AnnouncementsCosmo’s Rifamycin Gel Hits Key Phase 2 Mark in Distal Ulcerative Colitis1w ago

Company AnnouncementsCosmo’s GI Genius AI System Boosts Adenoma Detection in Major VA Study1M ago
Company AnnouncementsCosmo Pharmaceuticals to Change SIX Ticker to CMHC, Aligning Brand With Health-Focused Strategy2M ago
Company AnnouncementsCosmo lifts recurring revenues and advances dermatology and GI pipelines3M ago
Company AnnouncementsCosmo sets date for 2026 half-year results and investor webcast4M ago

Company AnnouncementsCosmo accelerates European rollout of first-in-class acne drug Winlevi4M ago

Company AnnouncementsCosmo and Glenmark roll out first-in-class acne drug Winlevi across key European markets4M ago

Company AnnouncementsCosmo completes Phase II recruitment for novel ulcerative colitis therapy5M ago

The FlyCosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright6M ago
Company AnnouncementsCosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings6M ago
Company AnnouncementsCosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend6M ago
Company AnnouncementsCosmo to Showcase Real-Time Medical AI Platforms at NVIDIA GTC 20267M ago

Company AnnouncementsCosmo Sets April General Meeting with Name Change and Payout on Agenda7M ago

Company AnnouncementsCosmo Pharmaceuticals Lifts Recurring Revenues, Boosts Dividend and Sets Growth Path to 20307M ago

Company AnnouncementsCosmo teams with Dutch institutions to expand GI Genius AI into Barrett’s esophagus detection8M ago

Company AnnouncementsCosmo Pharmaceuticals to Court Investors at Major 2026 Healthcare Conferences8M ago
Company AnnouncementsCosmo Pharmaceuticals Bolsters Institutional Base With Non‑Dilutive Treasury Share Placement9M ago
Company AnnouncementsCosmo Pharmaceuticals Sets 9 March 2026 Webcast for 2025 Full-Year Results9M ago
Company AnnouncementsCosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum9M ago

Cosmo Pharmaceuticals’ Breezula: A Promising Breakthrough in Hair-Loss Treatment with Significant Market Potential

RatingsCosmo Pharmaceuticals’ Breezula: A Promising Breakthrough in Hair-Loss Treatment with Significant Market Potential11M ago

Company AnnouncementsCosmo Pharmaceuticals Unveils Breakthrough Results for Male Hair Loss Treatment11M ago

Company AnnouncementsCosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in Brazil11M ago